• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Desrochers Christine claimed ownership of 81,465 shares

    6/21/23 4:09:27 PM ET
    $CFMS
    Industrial Specialties
    Health Care
    Get the next $CFMS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Desrochers Christine

    (Last) (First) (Middle)
    600 TECHNOLOGY PARK DRIVE
    4TH FLOOR

    (Street)
    BILLERICA MA 01821

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/12/2023
    3. Issuer Name and Ticker or Trading Symbol
    Conformis Inc [ CFMS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Interim CFO & Controller
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 81,465 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Denise E. Pedulla, Attorney-in-Fact for Christine Desrochers 06/21/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CFMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CFMS

    DatePrice TargetRatingAnalyst
    11/4/2021$2.50 → $2.00Outperform
    Oppenheimer
    9/22/2021$3.00 → $2.50Outperform
    Oppenheimer
    More analyst ratings

    $CFMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • restor3d Completes Acquisition of Conformis

      DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis' stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis' common stock ceased trading on the NASDAQ prior to the opening of the NASDAQ on September 5, 2023. "We are extremely excited to complete this important transaction and look forward to leveraging our combined portfolio to deliver personalized orthopedic solutions for the whole human body," said J. Kurt Jacobus, CEO o

      9/5/23 8:18:31 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

      BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co., LLC ("Glass Lewis"), have each recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS and Glass Lewis share its be

      8/23/23 8:00:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

      BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS shares its belief that the proposed merger with restor3d is in the best inte

      8/21/23 4:10:25 PM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      7/10/23 5:14:02 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      2/14/23 12:20:12 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      2/13/23 10:56:02 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer reiterated coverage on Conformis with a new price target

      Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.00 from $2.50 previously

      11/4/21 10:00:09 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Oppenheimer reiterated coverage on Conformis with a new price target

      Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.50 from $3.00 previously

      9/22/21 7:20:22 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Conformis Inc.

      15-12G - Conformis Inc (0001305773) (Filer)

      9/15/23 9:56:53 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form S-8 POS filed by Conformis Inc.

      S-8 POS - Conformis Inc (0001305773) (Filer)

      9/5/23 6:08:15 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form S-8 POS filed by Conformis Inc.

      S-8 POS - Conformis Inc (0001305773) (Filer)

      9/5/23 6:08:13 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Financials

    Live finance-specific insights

    See more
    • Conformis Reports First Quarter 2023 Financial Results

      BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip system revenue of $0.8 million, an increase of 3% year-over-year.Cash and cash equivalents of $37.8 million as of March 31, 2023.   Three months ended March 31,

      5/8/23 8:05:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023

      BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in access. Date and Time

      4/13/23 4:30:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results

      BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on a constant currency basis.Hip system revenue of $0.6 million, a decrease of 15% year-over-year.Cash and cash equivalents of $48.7 million as of December 31, 2022.First procedur

      3/1/23 4:05:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer

      BILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer. "We are pleased to announce the addition of Michael Fillion as Chief Operating Officer. Mike brings to this role 30 years of experience in manufacturing and operations with a strong focus in precision metal products, medical devices, continuous improvement, and strategic business planning," said Mark Augusti, President and Chief Executive officer. "I look forward to the contributions he will make as a member of the Conformis team." Michael Fillion Prior to joining Conformis, Michael served as the Executive Vice Pr

      4/1/22 5:00:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary

      BILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. "We are pleased to announce the addition of Denise Pedulla as Chief Legal Officer and Corporate Secretary. Her strong public company experience and leadership capabilities will help support our growth strategy and further strengthens our executive team," said Mark Augusti, President and Chief Executive Officer. "I look forward to the contributions she will make as a member of the Conformis team." Denise Pedulla Prior to joining Conformis, Denise served as the General Counsel and Corporate Secreta

      3/14/22 4:30:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant Reported

      BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing. "Conformis is pleased to welcome James Paiva as the new V.P. of U.S. Marketing. As we continue to advance our growth strategy, we are confident that James' extensive background in new product introductions and multi-channel marketing will help to strengthen Conformis brand recognition and position us to capitalize on anticipated growth in the ambulatory surgery center space," said Mark Augusti, President and Chief Executive Officer.  "I look forward to the contributions James will make as a member of Confo

      11/8/21 9:00:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Fischetti Gary P returned 10,470 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:51 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Johnston Philip W returned 19,273 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:47 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Augusti Mark A was granted 17,778 shares and returned 190,277 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:53 AM ET
      $CFMS
      Industrial Specialties
      Health Care